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treatment has been accompanied by a dramatic rise in overdose deaths in the United States. 1 In 2016, up to 32 000 deaths reportedly involved prescription opioids, 2 and the economic burden of prescription opioid overdose has been estimated to exceed $78bn (£59bn; €67bn) annually. 3 Despite all the evidence of harm, however, it remains unclear exactly how to determine if a patient with chronic pain has opioid addiction, or what criteria should serve as a gold standard in making a diagnosis of opioid use disorder (OUD) in this context. This is an important gap in the literature that hinders both evidence based care and research on the links between prescription opioids and OUD. In this editorial, we discuss the limitations of diagnosing OUD in people with chronic pain, and make several recommendations for further research.
The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, (DSM-5)
provides a widely used set of diagnostic criteria for OUD. These criteria, however, do not always apply to patients who are prescribed opioids for chronic pain. According to DSM-5, if a patient presents with two out of nine. Two of the 11 are excluded for this patient group] specific symptoms (box 1), it may indicate OUD. Symptoms 10 and 11-"tolerance" and "withdrawal"-are excluded from the list of diagnostic criteria for people taking opioids under medical supervision.
"Tolerance" and "withdrawal" were excluded in response to criticism that these physiological characteristics may simply be the natural consequences of extended opioid use, and do not necessarily indicate a pathological process in patients with pain. [4] [5] [6] Item: BMJ-UK; Article ID: klimas17092018; Article Type: Editorial; TOC Heading: Editorials; DOI: 10.1136/bmj.k3949
Nevertheless, many of the other criteria remain largely physiological, including the first two: "opioids being taken in larger amounts or over a longer period of time than intended" and "a persistent desire or unsuccessful efforts to cut down or control opioid use."
Like withdrawal and tolerance, these characteristics may be a product of mismanaged pain or physiological dependence, rather than OUD. [4] [5] [6] For example, persistent pain may cause a patient to take their prescribed opioid for longer than originally planned, or at higher doses. The same applies to criteria 4-"craving or a strong desire to use opioids"-which had no significant relationship with opioid misuse in a recent study of patients on long term treatment. 7 As a result, the DSM-5 criteria are of questionable validity for patients prescribed opioids for pain. This may be particularly true in primary care, where clinicians often receive inadequate training in both pain and substance use disorders. 8 The second matter surrounding the diagnosis of OUD in pain patients is inconsistent use and poor standardisation of alternative measures. The shortcomings of DSM-5 have led many clinicians and researchers to define misuse, in the context of chronic pain, as the presence of aberrant, drug related behaviours 9 13 such as failed pill counts, repeated reports of lost drugs, failed urine drug tests, and attempts to get opioids from multiple clinicians.
Although many studies have used aberrant behaviours as a proxy for OUD, 14 these measures are not standardised. Highly heterogeneous behaviours have been classified as aberrant, including use of cannabis. 11 13 This poor standardisation reduces the validity of aberrant behaviour measures as diagnostic criteria for OUD in patients with chronic pain.
Use of cannabis is particularly problematic, given the increasing evidence that cannabis may have additive analgesic effects when combined with opioids. 15 Many other factors hinder accurate and timely recognition of OUD among patients with pain, including a reluctance to diagnose overuse of prescription opioids because of stigma, suboptimal training, or fear of being at fault. It is also true that, although imperfect, DSM-5 criteria can be useful and some ambiguity will remain regardless of the diagnostic measure used.
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Given the high prevalence of both pain and OUD, we must develop more robust, accurate, and reproducible metrics for identifying opioid addiction specifically in people with chronic pain. The DSM-5 has yet to be validated in this patient group, and the line between pathology and physiological dependence is not well enough defined to allow the confident application of DSM-5 criteria in this context. The definition of "aberrant, drug related behaviour" as an alternative option remains highly variable despite frequent use by both researchers and clinicians. 
